Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIa Study to Evaluate the Safety and Efficacy of ABX464 Versus Placebo in Subjects With Moderate to Severe Active Ulcerative Colitis Who Have Failed or Are Intolerant to Immunomodulators, Anti-TNFα, Vedolizumab and/or Corticosteroids

NCT03093259 is registered in ClinicalTrials.gov with Abivax S.A. as lead sponsor.

NCT NCT03093259
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03093259 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIa Study to Evaluate the Safety and Efficacy of ABX464 Versus Placebo in Subjects With Moderate to Severe Active Ulcerative Colitis Who Have Failed or Are Intolerant to Immunomodulators, Anti-TNFα, Vedolizumab and/or Corticosteroids
Lead sponsor
Abivax S.A.
Phase
Phase 2
Overall status
Completed
Start date
November 16, 2017
Completion date
February 4, 2019
Enrollment
32 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis